2018 saw the failure of several large clinical trials that were based on the premise that reduction of amyloid-β levels is an effective treatment for symptomatic Alzheimer disease. Yet, over the same time period, good news also emerged about the diagnostic value of tau PET imaging.
Failures of anti-amyloid-β (Aβ) antibodies have highlighted gaps in understanding their dosing and the timing of their usage in the Alzheimer disease (AD) spectrum1,2.
The human clinical trials of BACE1 inhibitors cast doubt on this therapeutic approach but might provide valuable insights into the normal cellular and synaptic functions of Aβ and its precursor6.
Tau PET imaging shows excellent specificity and expected sensitivity for clinically diagnosed dementia with elevated Aβ8.
A new research framework offers researchers a common language for describing the Aβ, tau and neurodegeneration patterns of patients along the entire cognitive spectrum of AD10.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Cummings, J. L. et al. ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology 90, e1889–e1897 (2018).
Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 378, 321–330 (2018).
Rogers, M. B. A4 Researchers raise solanezumab dose, lengthen the trial. alzforum https://www.alzforum.org/news/research-news/a4-researchers-raise-solanezumab-dosage-lengthen-trial (2017).
McCaffrey, P. Second look at BAN2401 data still positive, despite snafu. alzforum https://www.alzforum.org/news/conference-coverage/second-look-ban2401-data-still-positive-despite-snafu (2018).
Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).
Egan, M. F. et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 378, 1691–1703 (2018).
Rogers, M. B. Bump in the road or disaster? BACE inhibitors worsen cognition. alzforum https://www.alzforum.org/news/conference-coverage/bump-road-or-disaster-bace-inhibitors-worsen-cognition (2018).
Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease versus other neurodegenerative disorders. JAMA 320, 1151–1162 (2018).
Roberts, R. O. et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol. 75, 970–979 (2018).
Jack, C. R. Jr et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).
This work was supported by NIH grants P50 AG16574, U01 AG06786 and R01 AG41851.
D.S.K. serves on a Data Safety Monitoring Board (DSMB) for The Dominantly Inherited Alzheimer Network (DIAN) study for which he receives personal compensation. He serves on a DSMB for Biogen, but all compensation related to that activity goes to his institution. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. He does not receive any personal compensation from either Biogen or Lilly as a site investigator; his institution receives funding for those activities. He is an adviser to Samus Pharmaceuticals and Alzeca Biosciences. For both, he receives no personal compensation; his institution receives funding for those activities. He receives research support from the NIH. Avid Radiopharmaceuticals, Inc., supplies Mayo Clinic with AV-1451 precursor, chemistry production advice and oversight, and FDA regulatory cross-filing permission and documentation that is used in research in which D.S.K. is an investigator.
Rights and permissions
About this article
Cite this article
Knopman, D.S. Bad news and good news in AD, and how to reconcile them. Nat Rev Neurol 15, 61–62 (2019). https://doi.org/10.1038/s41582-018-0131-7